Sivik Global Healthcare LLC Reduces Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Sivik Global Healthcare LLC decreased its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 67.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 140,000 shares of the company’s stock after selling 285,000 shares during the period. Sivik Global Healthcare LLC’s holdings in Maravai LifeSciences were worth $763,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Patriot Financial Group Insurance Agency LLC purchased a new stake in shares of Maravai LifeSciences during the fourth quarter worth about $136,000. SG Americas Securities LLC grew its stake in shares of Maravai LifeSciences by 7.3% during the fourth quarter. SG Americas Securities LLC now owns 33,046 shares of the company’s stock worth $180,000 after acquiring an additional 2,239 shares during the last quarter. FNY Investment Advisers LLC grew its stake in shares of Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after acquiring an additional 6,000 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Maravai LifeSciences by 1,172.4% during the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock worth $33,658,000 after purchasing an additional 3,731,924 shares during the period. Finally, Franklin Resources Inc. acquired a new stake in shares of Maravai LifeSciences during the third quarter worth about $600,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Trading Up 1.0 %

Shares of MRVI stock opened at $5.08 on Thursday. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -3.07 and a beta of -0.07. The stock has a 50 day simple moving average of $5.42 and a 200-day simple moving average of $7.20. Maravai LifeSciences Holdings, Inc. has a 1-year low of $4.28 and a 1-year high of $11.56.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Thursday, November 7th. The company reported ($0.09) earnings per share for the quarter. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The business had revenue of $65.20 million for the quarter, compared to analyst estimates of $67.58 million. During the same period in the previous year, the company earned ($0.02) earnings per share. On average, equities research analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Guggenheim assumed coverage on Maravai LifeSciences in a report on Thursday, December 19th. They set a “neutral” rating for the company. Wolfe Research assumed coverage on Maravai LifeSciences in a report on Thursday, November 14th. They set a “peer perform” rating for the company. William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. Royal Bank of Canada decreased their price target on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Finally, Robert W. Baird decreased their price target on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.28.

Insider Buying and Selling

In other news, insider Carl Hull purchased 175,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average cost of $5.64 per share, for a total transaction of $987,000.00. Following the completion of the transaction, the insider now owns 175,000 shares of the company’s stock, valued at $987,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 0.63% of the stock is owned by company insiders.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.